<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04024514</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-2019-0343</org_study_id>
    <nct_id>NCT04024514</nct_id>
  </id_info>
  <brief_title>Renal Protocol Protection in CKD Patients</brief_title>
  <official_title>Development of Renal Protection Protocol Using Low Dose Contrast Media and Spectral Computed Tomography in Chronic Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate whether acceptable image quality is achievable using low
      contrast media dose and low keV imaging in chronic kidney disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall image quality</measure>
    <time_frame>6 months after complete enrollment</time_frame>
    <description>qualitative scoring for image quality on five-point scale (1: worst, 5: excellent, representative value is average score)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast media (CM) dose</measure>
    <time_frame>3 months after complete enrollment</time_frame>
    <description>administered CM dose in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Contrast media-induced nephrotoxicity</measure>
    <time_frame>3 days after contrast media administration</time_frame>
    <description>serum Cr level increase by 25% or more of the baseline, or 0.5mg/dl in 3 days after contrast media administration without other cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Image contrast</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for image contrast on five-point scale (1: worst, 5: excellent, representative value is average score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion conspicuity</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>qualitative scoring for focal lesion depiction on five-point scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lesion (HCC) detection</measure>
    <time_frame>12 months after complete enrollment</time_frame>
    <description>detection rate of focal liver lesion/HCC on CT</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>HCC</condition>
  <condition>CKD</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low CT contrast media dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard CT contrast media dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>low dose CT contrast media</intervention_name>
    <description>CT contrast media (Ioversol 320mgI/kg) is administrated at a dose of 300mgI/kg in low dose group</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard dose CT contrast media</intervention_name>
    <description>CT contrast media (Ioversol 350mgI/kg) is administrated at a dose of 525mgI/kg in standard dose group.</description>
    <arm_group_label>Standard dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk group for developing HCC

          -  Scheduled contrast-enhanced CT for HCC diagnosis or surveillance

          -  chronic kidney disease (Estimated GFR &lt; 60mL/min/1.73m2)

        Exclusion Criteria:

          -  not a high risk group for developing HCC

          -  congestive hepatopathy

          -  on dialysis

          -  no venous access on forearm

          -  anticipated beam hardening artifact due to prosthesis

          -  relative/absolute contra-indication of contrast-enhanced CT except CKD (Estimated GFR
             &lt; 60mL/min/1.73m2)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Hee Yoon, MD</last_name>
    <phone>82-2-2072-2584</phone>
    <email>jhjhry@snuh.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>CT</keyword>
  <keyword>Spectral</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

